OLAPARIB
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Trial Timeline
Dec 22, 2016 → Dec 3, 2020
NCT ID
NCT02983799About OLAPARIB
OLAPARIB is a phase 2 stage product being developed by AstraZeneca for Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity. The current trial status is completed. This product is registered under clinical trial identifier NCT02983799. Target conditions include Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity.
What happened to similar drugs?
2 of 20 similar drugs in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity were approved
Approved (2) Terminated (2) Active (16)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03063710 | Pre-clinical | Completed |
| NCT05501548 | Phase 2 | Terminated |
| NCT04951492 | Phase 2 | Terminated |
| NCT05482074 | Phase 2 | Withdrawn |
| NCT05262608 | Phase 2 | UNKNOWN |
| NCT04884360 | Phase 3 | Active |
| NCT04515836 | Phase 2 | Recruiting |
| NCT04532645 | Pre-clinical | Completed |
| NCT04421963 | Phase 3 | Active |
| NCT04330040 | Approved | Completed |
| NCT04236414 | Phase 1 | Completed |
| NCT03782818 | Phase 1/2 | Terminated |
| NCT03829345 | Phase 2 | UNKNOWN |
| NCT03786796 | Phase 2 | Recruiting |
| NCT03955640 | Phase 1 | Terminated |
| NCT03742895 | Phase 2 | Active |
| NCT04152941 | Pre-clinical | Completed |
| NCT03570476 | Phase 2 | Terminated |
| NCT03470805 | Phase 2 | Completed |
| NCT03448718 | Phase 2 | Completed |
Competing Products
20 competing products in Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity